Kiniksa Pharmaceuticals International, plc
NASDAQKNSA delivered a sharp earnings-driven re-rating this week, with the stock jumping 25% in a single session to $79.44 — a move that left most analyst price targets instantly stale and forced a wave of same-day revisions. The analyst reaction was unusually unified in both direction and scale. JP Morgan raised its target from $72 to $107, maintaining Overweight, while Citigroup lifted…
KNSA short interest surges 33.6% in one week to 9.7% of float, highest level in months.
Snapshot as of 30 Jul 2026
KNSA delivered a sharp earnings-driven re-rating this week, with the stock jumping 25% in a single session to $79.44 — a move that left most analyst price targets instantly stale and forced a wave of same-day…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for KNSA — free to start on ORTEX.
Sign up for free →Open KNSA on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live KNSA data →